


Supplemental Figure 6



Supplementary Fig. 6: Effects of rogaratinib-containing combinations in the cell cycle of LTED-R FGFR1-overexpressing or amplified cell lines. Cell cycle charts of the different *in vitro* models in presence of vehicle or drug (monotherapy or combinations) for 48h. 1 μ M rogaratinib, 0.5 nM fulvestrant (MCF7 cell lines) or 1.5 nM (T47-D and HCC1428 cell lines) and 50 nM (MCF7) or 100 nM (T47-D and HCC1428) palbociclib. Gated areas: percentage of BrdU-positive cells.